ATTR-CM is more frequent in women than previously believed: study
ATTR-CM is thought to affect mainly men. But recent studies suggest that more women could have the disease than earlier thought.
News
-
-
Study offers a snapshot of patients with ATTR-CM in Australia and New Zealand
A study detailed the characteristics of people with the disease in ATTR-CM centers in the two Australasian countries.
-
Study suggests ATTR-CM can be detected before symptom onset
A systematic screening process for relatives of patients with transthyretin amyloid cardiomyopathy (ATTR-CM) has shown promising results.
-
Tafamidis reduced amyloid in ATTR-CM but showed no symptom improvement
The study results suggested that tafamidis may stabilize ATTR-CM progression rather than reverse its effects.
-
Single dose of ATTR therapy nucresiran reduced TTR levels, company says
Nucresiran showed potential as a treatment for transthyretin amyloidosis cardiomyopathy (ATTR-CM), Alnylam Pharmaceuticals said.
-
FDA approves acoramidis to treat ATTR-CM
The FDA says the drug is designed to reduce death and hospitalizations related to transthyretin cardiac amyloidosis (ATTR-CM).
-
Research suggests arginine holds prophylactic potential for patients at risk for ATTR-CM
Arginine helped stabilize TTR tetramers and prevented amyloid formation, showing its potential as a safe way to stave off ATTR-CM.
-
Sodium-glucose cotransporter-2 inhibitors could be useful for people with ATTR-CM
SGLT2is appeared to be safe for patients with ATTR-CM and may result in fewer hospitalizations and improved kidney function.
-
Study finds variability in signs of heart failure in patients with ATTR-CM
The study results highlighted the need to broaden diagnostic criteria for transthyretin amyloid cardiomyopathy, or ATTR-CM.
